AbbVie lifts 2026 EPS guidance, closes Apogee deal, posts Skyrizi and Juvmo approvals
Third-quarter revenue rose 10.3 percent as AbbVie raised full-year adjusted EPS guidance and reported positive late-stage data in HS and DLBCL.
SEC filing (6)
8 stories
Third-quarter revenue rose 10.3 percent as AbbVie raised full-year adjusted EPS guidance and reported positive late-stage data in HS and DLBCL.
SEC filing (6)
Supernus Pharmaceuticals said its common stock will be removed from Nasdaq following completion of a merger on November 2, 2026.
SEC filing
Indivior posted record quarterly SUBLOCADE sales and adjusted EBITDA as its all-stock merger with Supernus heads toward a November 2, 2026 close.
SEC filing
The company stopped work on its lead NK cell therapy after two patient deaths and weak durability data, and is now reviewing strategic options including a possible sale or dissolution.
SEC filing (4)
Supernus Pharmaceuticals ended its uncommitted revolving credit facility with UBS Bank USA on October 20, 2026, citing its pending combination with Indivior Pharmaceuticals.
SEC filing
FDA recognized seven years of orphan-drug exclusivity for ONAPGO starting February 3, 2025, as Supernus seeks a second manufacturing supplier with potential approval by mid-2027.
SEC filing (2)
The dividend will only be paid if Indivior's pending merger with Supernus Pharmaceuticals closes, expected on or about November 2, 2026.
SEC filing